

Long Noncoding RNA POU3F3 and α-Synuclein in Plasma L1CAM Exosomes Combined with β-Glucocerebrosidase Activity: Potential Predictors of Parkinson's Disease

Author links open overlay panelPeggyRentschabcSandyStayteacTimothyEganacIanClarkdBryceVisselaca Received 30 July 2019, Revised 17 October 2019, Available online 25 October 2019

L-dopa induced dyskinesia (LID) is a debilitating side-effect of the primary treatment used in Parkinson's disease (PD), l-dopa. Here we investigate the effect of HU-308, a cannabinoid CB2 receptor agonist, on LIDs. Utilizing a mouse model of PD and LIDs, induced by 6-OHDA and subsequent l-dopa treatment, we show that HU-308 reduced LIDs as effectively as amantadine, the current frontline treatment. Furthermore, treatment with HU-308 plus amantadine resulted in a greater anti-dyskinetic effect than maximally achieved with HU-308 alone, potentially suggesting a synergistic effect of these two treatments. Lastly, we demonstrated that treatment with HU-308 and amantadine either alone, or in combination, decreased striatal neuroinflammation, a mechanism which has been suggested to contribute to LIDs. Taken together, our results suggest pharmacological treatments with CB2 agonists merit further investigation as therapies for LIDs in PD patients. Furthermore, since CB2 receptors are thought to be primarily expressed on, and signal through, glia, our data provide weight to suggestion that neuroinflammation, or more specifically, altered glial function, plays a role in development of LIDs.

논문 보러가기 🄆

양이 적은 exosome sample에서 4개 단백질을 한꺼번에 확인할 수 있었던 이유?

Wes라서 가능했습니다!



High Sensitivity: 일반 WB보다 8배 높은 sensitivity
Less Sample & less Ab: 0.6ug Sample (최소농도 0.25mg/ml)
Multiplex Western: 최대 4개 targets 동시 분석 / sample

3hrs Run time: from loading to result

Full Automation: 높은 재현성 웅비 분석서비스 / 실험실 데모 가능

Wes에 대해 더 알고 싶으신가요? ❷ 응·테·나 신청하세요!



Immuno Assay Guide, 3D&Organoids, Single Cell Analysis, Dignostics, 등 다양한 주제

